Dysport vs. Jeuveau: Diffusion, Dosing Math, and Cost Compared (2026 Guide)

Dysport and Jeuveau both market themselves as cost-effective alternatives to Botox, and at first glance the patient-facing claims look similar — fast onset, 3–4 month duration, smoother glabellar lines. But under the hood these two products solve the value problem in opposite ways. Dysport is a slightly broader-spreading toxin dosed at a 2.5:1 ratio against Botox; Jeuveau is a Botox-like 900 kDa formulation dosed 1:1 with Botox and positioned as a “Newtox” aesthetics-only product.

This guide walks through what is genuinely different between Dysport and Jeuveau based on the FDA labels, the EV-001 and EV-002 phase trials behind Jeuveau, the head-to-head literature on Dysport, and the per-treatment pricing math you will actually see at a U.S. clinic in 2026.

What Dysport and Jeuveau Actually Are

Both are purified type A botulinum toxins. Both work by temporarily blocking acetylcholine release at the neuromuscular junction, relaxing targeted muscles and softening dynamic wrinkles. The chemistry of action is identical; the complex size, diffusion behavior, and manufacturing history are not.

• Dysport (abobotulinumtoxinA) — manufactured by Galderma, FDA-approved cosmetically for glabellar lines in April 2009. Dysport is a complex of roughly 500–900 kDa with a higher proportion of free 150 kDa active toxin. That looser complex is part of why Dysport diffuses slightly more than its peers.
• Jeuveau (prabotulinumtoxinA-xvfs) — manufactured by Evolus, FDA-approved cosmetically for glabellar lines in February 2019. Marketed as “Newtox” and as the first cosmetics-only neurotoxin in the U.S. The molecule is a roughly 900 kDa complex produced using the Hi-Pure proprietary process, which yields a profile that behaves much like Botox in tissue.

Short version: Jeuveau is closer to Botox in everything except price; Dysport is its own thing — a faster, broader-spreading product with a very different unit system.

Onset: When Will You See Results?

Both products onset relatively quickly, but Dysport has the slight edge.

• Dysport onset: Most patients see softening at 2–3 days, with peak effect around 10–14 days. Dysport is widely regarded as one of the fastest-acting cosmetic toxins on the U.S. market.
• Jeuveau onset: The EV-001 and EV-002 trials reported onset typically at 2–3 days, with peak effect around 10–14 days.

For most patients, the perceived onset difference between these two products is small. Dysport’s reputation for speed is genuine but modest. If you are racing the clock for an event nine to ten days out, either product is a reasonable choice.

Duration: How Long Will Results Last?

Essentially the same.

• Dysport: Typical glabellar duration is 3–4 months. The FDA label notes effects “may last up to 4 months” and re-treatment no more often than every 3 months.
• Jeuveau: Typical glabellar duration is also 3–4 months, in line with Botox and other 900 kDa formulations.

Head-to-head and parallel-study data have not shown a consistent, clinically meaningful duration advantage for one over the other. Real-world duration is driven much more by your metabolism, dose adequacy, treatment area, and injection technique than by which of these two products is in the syringe. If duration is the single priority that matters most to you, the longer-acting option to discuss with your injector is Daxxify, which is studied at six months median duration.

Dosing and Unit Conversion

This is where the two products diverge most on paper.

Per the FDA labels:

• Dysport for glabellar lines: 50 units total, divided across 5 injection sites (10 units each). Roughly 2.5–3 units of Dysport equal 1 unit of Botox.
• Jeuveau for glabellar lines: 20 units total, divided across 5 injection sites (4 units each). The dosing ratio against Botox is approximately 1:1.

So a typical Dysport patient and a typical Jeuveau patient leaving with the same clinical result will have received 50 units versus 20 units. Per-unit price comparisons between these two products are misleading — the only meaningful comparison is total per-treatment cost. The FDA labels explicitly warn that units are not interchangeable across brands, so any competent injector recalculates from scratch when switching you between them.

Diffusion and Precision

This is one of the two most important practical differences between Dysport and Jeuveau.

Dysport tends to diffuse — spread outward from the injection point — slightly more than Botox-class products. That makes it well-suited for broad, flat areas:

• Forehead, where you want even softening across a wide muscle with fewer injection points
• Patients who want fewer needle pricks per session

Jeuveau diffuses tightly, similar to Botox. The Hi-Pure 900 kDa complex behaves predictably and stays close to where it is placed. That makes Jeuveau a comfortable choice for:

• Crow’s feet, where you do not want toxin drifting toward muscles that move your smile
• Lip flips and small perioral targets
• Bunny lines, chin dimpling, and other focal areas

For a glabellar-only patient, the diffusion difference is rarely the deciding factor. For a forehead-heavy patient, Dysport’s spread is a feature. For a precision-sensitive patient, Jeuveau’s tighter footprint behaves like the Botox they already know.

Cost: What You Will Actually Pay in 2026

Both products are positioned below Botox on price, but the math gets there differently.

• Dysport: roughly $4–$7 per unit. A standard glabellar treatment of 50 units lands around $250–$350.
• Jeuveau: roughly $8–$12 per unit. A standard glabellar treatment of 20 units lands around $200–$280.

Jeuveau is marketed as a 20–30% discount to Botox. Dysport often lands at a similar total per-treatment cost despite its lower per-unit number, because you are using 2.5 times more units. For a glabellar-only patient, Jeuveau often comes in modestly cheaper per treatment. For a forehead-plus-glabellar patient, the per-unit math tilts back toward Dysport.

Be careful comparing clinics that quote “per area” instead of “per unit” — per-area pricing can hide undertreatment.

Side Effects and Safety

Both products carry essentially identical short-term side effect profiles, because the mechanism of action is identical. In FDA-controlled trials, the most common adverse events for both were:

• Headache (3–11%)
• Injection-site reactions — bruising, redness, mild swelling (1–5%)
• Eyelid drooping (ptosis), typically less than 1% in trained hands
• Asymmetric brow position, usually correctable with a small touch-up at the two-week mark

Both products carry the FDA boxed warning regarding the theoretical possibility of distant toxin spread; at cosmetic facial doses, this has not been a clinically meaningful concern across millions of treatments.

The most important safety variable is not the brand — it is the injector. Choose a board-certified provider with extensive injection volume in the product they are using.

Who Is the Ideal Candidate for Each?

Dysport may be the better fit if:

• You are treating broad areas like the forehead
• You want the slight edge on onset speed (often 2–3 days)
• You like the idea of fewer injection points per session
• You are a larger-area patient where per-unit pricing efficiency matters

Jeuveau may be the better fit if:

• You have done well on Botox and want a clinically similar, modestly cheaper option
• You are treating focal areas where you want a tightly localized effect
• You prefer a Botox-like 1:1 dosing experience and find the Dysport unit math confusing
• You are price-sensitive but not interested in the broader Dysport spread profile

Can You Switch Between Dysport and Jeuveau?

Yes. There is no medical reason you cannot alternate between these products from one treatment to the next, though most patients tend to settle on one or the other once they have tried both. A few practical notes:

• Always tell your new injector exactly which product you previously had, the dose, and roughly when. The unit counts (50 vs. 20) are not interchangeable.
• You cannot stack the two in the same treatment area in the same session.
• Switching products does not reduce the (very small) risk of antibody formation against either toxin.
• Patients switching from Dysport to Jeuveau commonly report a tighter, more localized feel; those going the other direction sometimes describe a slightly broader softening.